Mammary Cell News Volume 2.36 | Sep 23 2010

May 12, 2022

Mammary Cell News 2.36 September 23, 2010.

In this issue: Science News | Current Publications | Industry News | Policy News | Events

TOP STORY

Mayo-Led Researchers Discover Genetic Variants Modifying Breast Cancer Risk

Individuals with disrupting mutations in the BRCA1 gene are known to be at substantially increased risk of breast cancer throughout their lives. Now, researchers show that some of those persons may possess additional genetic variants that modify their risk. [Press release from Mayo Clinic discussing online prepublication in Nature Genetics]

New Defined Medium – EpiCult^®-C
For Robust Growth of Human Mammary Luminal and Myoepithelial Cells
by STEMCELL Technologies

REQUEST A FREE SAMPLE

SCIENCE NEWS

Krag Publishes Largest-Ever Breast Cancer Surgery Study
A less invasive surgical procedure for detecting breast cancer spread has for the first time been proven to achieve the same cancer survival and recurrence control as traditional lymph node removal surgery in patients whose initial sentinel node biopsy tested negative for cancer. [Press release from The University of Vermont discussing online prepublication in The Lancet Oncology]

Molecule 968 Binds Glutaminase and Starves Cancer Cells, say Cornell Biologists
A molecule – simply called 968 – can starve cancer cells and the tumors they produce, says new research. [Press release from Cornell University discussing online prepublication in Cancer Cell]

Fat Stem Cells Safe for Breast Reconstruction when Cancer is Dormant, Says Pitt Team
Fat-derived stem cells can be safely used to aid reconstruction of breast tissue after mastectomy as long as there is no evidence of active cancer, according to researchers. [Press release from the University of Pittsburgh discussing online prepublication in Tissue Engineering Part A]

Stress Before Cancer Therapy Could Help Deadly Cells Survive Treatment, Lead to Disease Recurrence
Patients who experience physical or psychological stress – including rigorous exercise – one or two days before a cancer treatment might be unknowingly sabotaging their therapy, new research suggests. [Press release from the Ohio State University discussing online prepublication in Molecular Cancer Research]

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
Researchers describe a small molecule inhibitor that blocks oncogenic transformation induced by various Rho GTPases in fibroblasts, and the growth of human breast cancer and B lymphoma cells, without affecting normal cells. [Cancer Cell]

CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
This study identified chondroitin sulfate proteoglycan 4 (CSPG4) as a new target for triple-negative breast cancer (TNBC). The antitumor activity of CSPG4-specific monoclonal antibody was mediated by multiple mechanisms, including the inhibition of signaling pathways crucial for TNBC cell survival, proliferation, and metastasis. [J Natl Cancer Inst]

The Wnt Antagonist Dickkopf-1 Increases Endothelial Progenitor Cell Angiogenic Potential
By studying 62 human breast tumors, researchers found a significant positive correlation between Wnt antagonist Dickkopf-1 (DKK1) expression and von Willebrand factor. In vivo, DKK1 strongly enhanced the vascularization of Matrigel plugs and increased tumor size in a xenograft model of human breast carcinoma in nude mice. [Arterioscler Thromb Vasc Biol]

IGFBP-3 can Either Inhibit or Enhance EGF-Mediated Growth of Breast Epithelial Cells Dependent Upon the Presence of Fibronectin
Researchers have examined the effects of an insulin-like growth factor binding protein (IGFBP-3) on EGF-responses of breast epithelial cells in the context of changes in the extracellular matrix. [J Biol Chem]

Hsp27 Protects Adenocarcinoma Cells from UV-Induced Apoptosis by Akt and p21-Dependent Pathways of Survival
The results showed that Hsp27 expression and its direct chaperoning interaction increases Akt stability, and p21 phosphorylation and nuclear-to-cytoplasm translocation, both essential effects for the survival of UV-induced DNA-damaged cells. [Mol Cancer Res]

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Researchers compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior endocrine therapy. [J Clin Oncol]

Sentinel-Lymph-Node Resection Compared with Conventional Axillary-Lymph-Node Dissection in Clinically Node-Negative Patients with Breast Cancer: Overall Survival Findings from the NSABP B-32 Randomised Phase III Trial
The aims of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-32 were to establish whether sentinel-lymph-node resection in patients with breast cancer achieves the same survival and regional control as axillary-lymph-node dissection, but with fewer side-effects. [Lancet Oncol]

INDUSTRY NEWS

Celldex Therapeutics Announces Initiation of Randomized Phase IIb Clinical Trial of CDX-011 in Advanced Breast Cancer
Celldex Therapeutics, Inc. announced that the first patient has been treated in a randomized Phase IIb study of the Company’s CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. [Celldex Therapeutics, Inc. Press Release]

Celsion Announces ThermoDox(R) Abstract Accepted at the 2010 Breast Cancer Symposium
Celsion Corporation announced that an abstract on its Phase I/II DIGNITY trial of ThermoDox(R) in Recurrent Chest Wall (RCW) Breast Cancer has been accepted for a poster session at the 2010 Breast Cancer Symposium. [Celsion Corporation Press Release]

Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer
Boehringer Ingelheim announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. [Boehringer Ingelheim Press Release]

Genentech Provides Update on Avastin for Advanced Breast Cancer
Genentech, Inc., announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin® (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment. [Genentech, Inc. Press Release]

POLICY NEWS

NHGRI Funds Development of Third Generation DNA Sequencing Technologies
More than $18 million in grants to spur the development of a third generation of DNA sequencing technologies was announced by the National Human Genome Research Institute. [National Institutes of Health, United States]

Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44) (RFA-CA-10-013) [National Institutes of Health, United States]

Prospective Grant of Exclusive License: The Development of Immunotoxins/Targeted Toxins for the Treatment of Human Cancer (FR Doc. 2010-22844) [National Institutes of Health, United States]

National Human Genome Research Institute; Notice of Closed Meeting (FR Doc. 2010-23027) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-23144) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23143) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23275) [National Institutes of Health, United States]

Agenda for the Public Workshop on Cell and Gene Therapy Clinical Trials in Pediatric Populations [Food and Drug Administration, United States]

JOB OPPORTUNITIES

Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Mammary Cell News: Archives | Events | Subscribe | Contact Us